
2
Archived Theses
0
DOIs Assigned
0%
DOI Rate
Discipline
İnsan fibroblast hücre hatlarından uyarılmış pluripotent kök hücre eldesi
Objective: Induced pluripotent stem cells (iPSCs) possess the remarkable abilities to differentiate into cell types from all three germ layers and to self-renew indefinitely. These features make them highly valuable for in vitro modeling of human biology and gene and cell therapies. However, current methods for iPSC generation are often inefficient and require prolonged culture periods, necessitating improved protocols with enhanced safety and efficacy. In this study, we aimed to reprogram HFF-1 human fibroblasts into iPSCs using integration-deficient lentiviral vectors (IDLV-OSKs) encoding the reprogramming factors Oct4, Sox2, and Klf4, along with sodium butyrate as a supporting small molecule to increase efficiency. Methods: In our study, IDLV-OSK vectors encoding the transcriptional regulators Oct4, Sox2, and Klf4 were used to reprogram HFF-1 fibroblast cells into pluripotency. In addition to the viral vector, the epigenetic modulator sodium butyrate, which is a histone deacetylase inhibitor, was used as a supportive molecule. With our applied reprogramming protocol, colonies suitable for passaging were obtained within 9–12 days. The resulting iPSCs were characterized morphologically and also by the expression of pluripotency markers expressed on the cell surface (alkaline phosphatase, Tra-1-81, Tra-1-60) and those located in the nucleus (Oct4, Klf4, c-Myc, Nanog). Results: We generated iPSCs using IDLV-OSKs with the support of a histone deacetylase inhibitor. The resulting colonies exhibited the expected morphological characteristics. The expression of surface and nuclear pluripotency markers was demonstrated in the colonies. Conclusion: Our findings demonstrate that IDLV-OSK vectors, along with sodium butyrate, constitute an efficient and potentially safe approach for reprogramming human fibroblasts into iPSCs with our protocol. This method holds promise for efficient and safer applications in disease modeling and the development of experimental therapeutic strategies. Keywords: Induced pluripotent stem cells, Sodium butyrate, Lentiviral vectors
The possible anti-tumoral/anti-metastatic effects of BMP1 inhibitor alone or in combination with doxorubicin on metastatic breast carcinoma
Objective: Preventing distant organ metastases is critical for reducing mortality in metastatic breast cancer. Current treatments are insufficient in preventing spread and are limited by resistance and side effects. Doxorubicin (DOX) suppresses tumor progression but causes cardiotoxicity and resistance. Bone morphogenetic protein-1 (BMP-1), a metalloproteinase involved in tumor microenvironment and extracellular matrix remodeling, supports metastasis and poor prognosis. BMP-1 inhibitors may reshape the tumor microenvironment, reduce metastasis, and enhance chemotherapy effectiveness. This thesis aimed to evaluate the effects of the BMP-1 inhibitor UK-383367, alone and in combination with DOX, on tumor progression, lung and liver metastasis, immune cell subpopulations, and cytokine responses in in vivo breast cancer models. Method: In vivo models were established using 4TBM and 4TLM cell lines in BALB/c female mice, and tumor volume, lung and liver metastatic burden, distribution of immune cell subpopulations, and cytokine levels (TNF-α, IL-6, IL-10, IFN-γ) were evaluated. Results: Treatment with UK alone was found to reduce the lung metastatic burden and support T cell-mediated immune responses; however, it showed limited effects on primary tumor volume. DOX alone resulted in reduced tumor volume and metastatic spread while activating the immune response. The combination treatment of UK and DOX was observed to most effectively reduce tumor volume and metastatic burden, enhance the cytotoxic T cell response, and decrease immunosuppressive cell populations. Cytokine analyses revealed that IL-6 and IFN-γ levels increased in the treatment groups, while IL-10 levels exhibited context-dependent variability. Conclusion: The results of our study demonstrated that targeting BMP-1 represents a promising approach in the treatment of metastatic breast cancer, and that the combination of UK-383367 and DOX has the potential to reduce metastatic spread and support the immune response. Key words: BMP-1, UK-383367, Doxorubicin, Metastatic Breast Cancer, Immune response, Tumor microenvironment